Ankur Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.13 M
- Company Age 38 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.50 M
- Revenue Growth -15.17%
- Profit Growth 60.64%
- Ebitda 23.08%
- Net Worth 45.65%
- Total Assets 11.01%
About Ankur Pharmaceuticals
Ankur Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 October 1986 and has a history of 38 years and three months. Its registered office is in Kanpur Dehat, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.13 M.
The company has closed loans amounting to ₹1.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Madhu Bhargava, Shivani Bvhargava, and Sandeep Bhargava serve as directors at the Company.
Company Details
-
Location
Kanpur Dehat, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24231UP1986PTC008301
-
Company No.
008301
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
22 Oct 1986
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Ankur Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madhu Bhargava
|
Director | 22-Oct-1986 | Current |
|
Shivani Bvhargava
|
Director | 31-Oct-1998 | Current |
|
Sandeep Bhargava
|
Additional Director | 10-May-2021 | Current |
Financial Performance of Ankur Pharmaceuticals.
Ankur Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 15.17% decrease. The company also saw a substantial improvement in profitability, with a 60.64% increase in profit. The company's net worth Soared by an impressive increase of 45.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ankur Pharmaceuticals?
In 2017, Ankur Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Ugma Laboratories Private LimitedMadhu Bhargava, Shivani Bvhargava and 1 more are mutual person
Charges (Loans)
₹0
₹1.50 M
Charges Breakdown by Lending Institutions
- Icici Hfc Ltd. : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Mar 2004 | Icici Hfc Ltd. | ₹1.50 M | Satisfied |
How Many Employees Work at Ankur Pharmaceuticals?
Unlock and access historical data on people associated with Ankur Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ankur Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ankur Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
